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Antioxidants can decrease oxidative stress and combined with acute exercise they may lead to further decreases in blood pressure.
The purpose of this study was to investigate the eﬀects of 2 weeks of antioxidant supplementation on vascular distensibility
and cardiovascular hemodynamics during postexercise hypotension. Methods. Twenty young subjects were randomized to
placebo (n = 10) or antioxidant supplementation (n = 10) for two weeks. Antioxidant status, vascular distensibility, and
hemodynamics were obtained before, immediately, and 30 minutes after an acute bout of aerobic exercise both before and after
supplementation. Results. Two weeks of antioxidant supplementation resulted in a greater systolic blood pressure (SBP) decrease
duringpostexercisehypotension(PEH)andsigniﬁcantdecreasesinaugmentationindexversusplacebo(12.5%versus3.5%,resp.).
Also ferric-reducing ability of plasma (FRAP) increased signiﬁcantly (interaction P = 0.024) after supplementation. Conclusion.
Supplementation showed an additive eﬀect on PEH associated with increased FRAP values and decreases in systolic blood pressure
and augmentation index.
1.Introduction
Hypertension is deﬁned as an elevation of blood pressure
at or above a systolic blood pressure (SBP) of 140mmHg
and/or a diastolic blood pressure (DBP) of 90mmHg. Pre-
hypertension is designated as a systolic pressure from 120
to 139mmHg or a diastolic pressure from 80 to 89mmHg
[1]. Chronic hypertension degrades the elastic properties
of the arterial walls, leaving the vessel less compliant and
unable to absorb the high energy of arterial outﬂow [2].
Healthy, large arteries contain elastin, smooth muscle, and
collagen which allow them to be acquiescent and buﬀer
the pressure change due to ventricular ejection [3]. This
reduction in elasticity termed arterial stiﬀness leads to an
increase in systolic blood pressure and a decrease in diastolic
BP resulting in an increase in pulse pressure which has been
shown to increase cardiovascular risk.
Hypertension is widespread in the western world and
it imposes a substantial burden on health care costs in
the United States. According to the TROPHY study, it is
possible to delay the progression from prehypertension to
hypertension with medication [4], however this strategy will
expose tens of millions of individuals to patienthood and
expensive pharmacologic treatments and unfavorable side
eﬀects that may be due to reactive metabolites [5]. Non-
pharmacological treatments such as antioxidant treatments
have been proven safe [6] and are in demand in order to
ease the burden on costs and negative side eﬀects associated
with hypertension medications. However, there is little data
showing evidence of one particular ﬂavonoid having a
signiﬁcanteﬀectontheaforementionedvascularparameters.
Therefore, a compound of multiﬂavonoids may exude a
more favorable eﬀect on cardiovascular variables by increas-
ing the bioavailability and absorption of the ingredients
within the compound. Alternatively, it has been shown that
there is a decrease in blood pressure called postexercise
hypotension(PEH)followinganacuteboutofexercisewhich
could potentially be an eﬀective treatment for elevated blood
pressure.PEHcouldbetheﬁrstlineofdefenseagainsthyper-
tension in order to control blood pressure and therefore2 Oxidative Medicine and Cellular Longevity
prevent disease. Additionally, antioxidant supplementation
has been shown to decrease blood pressure by increasing
endothelial nitric oxide synthase (eNOS) which will reduce
acuteexercise-inducedinﬂammationandoxidativestress[7–
10]. Flavonoids in particular are strong antioxidants due
to their low redox potential and capacity to donate several
electrons or hydrogen atoms and the most widespread of all
ﬂavonoids is quercetin. In addition, both epigallocatechin
3-gallate (EGCG) and ﬁsh oil have beneﬁcial eﬀects on
cardiovascular health and have been shown to decrease
systolic blood pressure and enhance arterial elasticity [11,
12].
If it is possible to further decrease blood pressure during
PEH due to these antioxidants and omega-3s, supplemen-
tation may be more favorable than pharmacological anti-
hypertensives. The primary focus of this study was to
investigate the potential additive eﬀects of a novel omega-
3 plus multiﬂavonoid supplement combined with aerobic
exercise on PEH in young pre-hypertensives. We hypoth-
esized that the supplement in combination with aerobic
exercise will show an additive decrease in postexercise blood
pressure (BP) and pulse wave velocity (PWV) changes while
increasing arterial distensibility.
2.MaterialsandMethods
2.1. Participants. Prior to the start of this study, all methods
were reviewed and approved by the University Institutional
Review Board. Twenty participants (18 male, 2 female), 18–
26 years old, were recruited through posters/ﬂiers located
throughout the University Community. Participants on any
medication, including aspirin or birth control, and/or with
knowncardiovasculardisease,diabetes,orhypertensionwere
excluded. Prior to the start of the study, each subject gave
written informed consent and completed health history and
lipid proﬁle questionnaire to assess prior activity level [13].
The sample size of 10 subjects per group was based on
previous data from our laboratory gathered under similar
conditions. For these calculations, the STATA statistical soft-
ware package was used (College Station, TX) to determine
the number of subjects to give us adequate statistical power.
We based our calculations on two dependent variables (MAP
and Aix) and found their power to be 0.92 and 0.90,
respectively, for the present sample size at a P  0.05.
2.2. Study Design. Participants reported to a temperature
controlled laboratory (22.5–23.5 degrees Celsius) on four
separate occasions. Visit 1 consisted of informed consent,
group randomization, body composition assessment (DEXA
scan), and a laboratory equipment familiarization including
laboratory equipment data collection procedures. This was
followed by a graded exercise to test volitional exhaustion
performed on a treadmill to determine VO2peak.
The second visit consisted of a 12-hour fasted blood
draw taken at 0700 hours by a certiﬁed phlebotomist in
the laboratory. A 20mL blood draw was obtained with the
subject in the seated position using the antecubital vein. The
blood was immediately centrifuged and the resulting plasma
was aliquoted into cryovials and frozen in liquid nitrogen
for later analyses of ferric-reducing ability of plasma and the
oxygenradicalabsorbancecapacity(FRAP,ORAC,resp.)and
hematocrit.
Upon entering the laboratory for Visit 3, the subject
was seated and rested quietly for 15 minutes and had a
resting blood pressure taken in their left arm using a manual
sphygmomanometer and a stethoscope using the ﬁrst and
fourth Korotkoﬀ sounds for SBP and DBP, followed by pulse
wave analysis (augmentation index, AIx) measurements in
the radial artery. Next, the subject was placed in a supine
position and rested quietly for 10 minutes. Pulse wave
velocity measurements were taken and then the subject
was left in a quiet, darkened room while beat to beat
blood pressure measurements were recorded for 10 minutes.
Following these cardiovascular measures, the participants
underwent a preexercise blood draw before running on the
treadmill at a speed that elicited 65–70% of VO2peak HR
for 30 minutes. Immediately following the termination of
the exercise session, each participant underwent a seated
postexercise blood draw and blood pressure measurement.
Immediately following the blood draw and 30 minutes after
exercise, each participant had the same measurements taken
(AIx, pulse wave velocity and beat to beat measurements)
immediately after and then 30 minutes following exercise.
After the third visit, the participants started a 14-day
supplementation of an antioxidant mixture of quercetin,
isoquercetin, omega 3 fatty acids, and EGCG, or a placebo.
Both supplements were similar in composition and taste
to a candied fruit chew, however the placebo lacked the
active ingredients. The antioxidant daily dosage consisted of
1000mg quercetin with 120mg EGCG, 400mg isoquercetin,
and 400mg omega 3 fatty acids from ﬁsh oil. The par-
ticipants were instructed to take four chews a day of the
supplement, with two taken immediately prior to lunch
and two chews ingested immediately prior to dinner. All
subjects were asked to maintain their daily eating habits and
to return the empty packets of supplements at their next
laboratory visit. Once the fourteen-day supplementation was
completed, the participants reported back to the lab within
24 hours for the fourth visit and underwent the battery of
tests performed in visit 3.
Due to the confounding nature of estrogen on our
cardiovascular parameters, the female participants had to
arrange their supplementation and visits around their
menstrual cycle and one female was counterbalanced for
each treatment. Both visits two and three were performed
on day two of their menstrual cycle, and supplementation
commenced two weeks later; therefore when the fourteenth
day of supplementation was ﬁnished, the female participants
were on day two of their cycle for visit four.
3. Description of Procedures
3.1. DEXA Scan. “Dual Energy X-ray Absorptiometry” or
DEXA is a commonly used test for measuring bone mineral
density and one of the most accurate ways to determine body
composition. Subjects were placed in a Hologic DiscoveryOxidative Medicine and Cellular Longevity 3
QDR scanner in the supine position with their legs rotated
inward to 25 degrees and a whole body scan was performed.
Each scan was downloaded and analyzed by the same trained
technician in one session.
3.2. VO2peak Exercise Testing. Aerobic exercise capacity was
assessed using a modiﬁed Armstrong protocol, brieﬂy, the
subject begins the test at a comfortable running pace
(between 5.0 and 6.0 miles per hour) at 0% grade with the
incline increasing 2.5% every two minutes until volitional
fatigue was reached. If the subject did not reach fatigue when
the grade reached 10%, the speed was then increased by
2mph every 2 minutes. Heart rate was measured using a
Polar Heart Rate Monitor (Polar Electro, Inc., Woodbury,
NY, USA) and was recorded once during the ﬁnal 15
seconds of every stage, along with a rating of perceived
exertion RPE (Borg, 6–20). Expired air was collected con-
tinuously throughout the test and analyzed using a Quark
b
2 breath-by-breathmetabolicsystem(Cosmed,Rome,Italy)
for oxygen consumption, CO2 production, and respiratory
exchangeratio.VO2peak wasdeterminedbyaveragingtheVO2
values over the ﬁnal 15 seconds of exercise. Maximal eﬀort
was considered to have been reached when participants met
three of the following four criteria: (a) an RER of 1.15 or
greater; (b) a plateau in HR despite an increase in workload;
(c) a ﬁnal RPE score of 17 or greater on the Borg scale
(scale 6–20); and/or (d) a plateau in oxygen uptake despite
an increase in workload.
3.3. Pulse Wave Velocity (PWV). All measurements were
conducted in accordance with guidelines set forth by the
Clinical Application of Arterial Stiﬀness, Task Force III
[14]. A SphygmoCor was used to obtain the pulse wave
between (1) the left common carotid artery and the left
femoral artery and (2) the left common carotid and the left
dorsalis pedis artery. Distance from the carotid sampling
site to the midpoint of the manubrium sterni, manubrium
sternum to femoral artery, and carotid to the midpoint of
themanubriumsterni,manubriumsternumtodorsalispedis
was measured between these points as straight lines with a
tape measure. The distance from the carotid artery to the
manubrium sterni was subtracted from the manubrium to
femoralartery distance. PWV was determined fromthe foot-
to-foot ﬂow wave velocity. The foot of the pressure wave was
identiﬁed visually as the point of systolic upstroke. The time
delay between a minimum of 15 simultaneously recorded
ﬂow waves was averaged. PWV will then be calculated from
thedistancesbetweenmeasurementpointsandthemeasured
time delay (Dt) between proximal and distal foot waveforms
as follows: PWV = D/Dt (m/s), where D is distance in
meters and Dt is the time interval in seconds. Values attained
from carotid to femoral artery were taken as an index of
central compliance, while values attained from the carotid
and radial artery along with the measurement from the
femoral to dorsalis pedis were taken as an index of peripheral
compliance. All data was stored and analyzed oﬀ line after
completion of testing.
3.4. Hemodynamic Monitoring. Beat-to-beat blood pressures
were determined via the Finometer (FMS, Amsterdam, The
Netherlands). With participants in a supine position in
a quiet and darkened room, beat-to-beat blood pressures
were recorded for 10 minutes via ﬁnger plethysmography.
This noninvasive measurement of the change in blood
pressure has been shown to be reliable when compared
withmeasurementsofintra-arterialbloodpressure[15].The
brachial blood pressure was obtained using an integrated
brachial blood pressure cuﬀ and brachial BP waveforms were
reconstructed from ﬁnger arterial waveforms by applying
an inverse transfer function, a waveform ﬁlter, a level
c o r r e c t i o n ,a n dal e v e lc a l i b r a t i o n[ 16]. This has been shown
to increase the correlation between ﬁnger and proximal
arterial blood pressure values, allowing pressure values
to remain within the American Association for Medical
Instrumentation (AAMI) standards for the evaluation of
automated sphygmomanometers [17].
3.5. Analyses: Biomarkers of Oxidative Stress. Fasted blood
s a m p l e sw e r ed r a w nf r o ma na n t e c u b i t a lv e i nw i t hp a r -
ticipants in a seated position. The blood samples were
centrifuged in EDTA tubes, and plasma was aliquoted and
stored at 80◦C prior to analysis for plasma antioxidant
parameters Ferric Reducing Ability of Plasma (FRAP) and
Oxygen Radical Absorptive Capacity (ORAC).
3.5.1. FRAP. Total plasma antioxidant potential was deter-
mined by the FRAP assay according to the methodology of
Benzie and Strain [18]. The basis of this assay is that water
soluble reducing agents (antioxidants) in the plasma will
reduce ferric ions to ferrous ions, which then react with an
added chromogen. Samples and standards were analyzed in
duplicate and expressed as ascorbate equivalents based on
an ascorbate standard curve (0–1000µmol). Intra-assay and
interassay coeﬃcients of variation were less than 5% and 7%,
respectively.
3.5.2. ORAC. The ORAC assay was a modiﬁcation of the
methodology of Ou et al. [19]. Trolox standards were
made from a trolox stock solution. A serial dilution of
a5 0 µM trolox solution was made with phosphate buﬀer
solution to produce 25, 12.5, and 6.25µM trolox standards.
A ﬂuorescein (Aldrich Chemicals) working solution was
made by pipetting 800µL of stock solution into 50mL
phosphate buﬀer in a 50mL conical tube. Before use, the
solution was incubated in the water bath at 37◦C until thor-
oughly heated. The 2,2 -azobis-2-methyl-propanimidamide,
dihydrochloride (AAPH) solution was made by dissolving
0.108g of AAPH (Wako Chemical) into 5mL of incubated
phosphate buﬀer immediately before the start of the assay.
The microplate was prepared and loaded in a “forward-
then-reverse” order to avoid possible positional errors. The
edge wells were left empty or blank (phosphate buﬀer
working solution) to reduce the impact of “edge eﬀect”
on samples and standards particularly from temperature
eﬀects on the outside wells. Twenty µL of sample, blank,
and trolox standard solutions were pipetted into appropriate
wells. Then, 200µL ﬂuorescein working solution were added
to each well using an 8-channel micropipettor. A cover4 Oxidative Medicine and Cellular Longevity
Table 1: Participant characteristics.
Variable Treatment Placebo
n 10 10
Age (yr) 21.6 ± 0.62 20.7 ± 0.30
Height (cm) 177.4 ± 2.08 177.3 ± 2.57
Body mass (kg) 76.05 ± 3.24 75.55 ± 6.05
Peak oxygen consumption
(mL/kg/min)
53.9 ± 3.88 47.9 ± 3.01
was placed on the microplate and the plate and contents
incubated at 37◦C for at least 20 minutes. Then, 20µL
AAPH working solution were added using an 8 channel
micropipettor as quickly as possible. Final ORAC values
(µM/L trolox) were made from the plate reader derived area
under the curve (AUC). Then, the ﬁnal ORACFL values were
calculated by using a quadratic regression equation x =
−b ±
√
b
2 − 4ac +4 cy. Excitation wavelength was 485nm
and emission wavelength was 520nm. Intra-assay and inter-
assay coeﬃcients of variation were less than 5% and 7%,
respectively.
3.6. Statistical Analysis. Student’s t-test for unpaired values
was used to evaluate the statistical diﬀerences in descriptive
characteristics between groups. An ANOVA with repeated
measures (group (treatment versus placebo) by time (base-
linepreversuspost)byexercisetreatment(beforeversusafter
versus after 30)) was performed on all dependent variables.
If a signiﬁcant interaction was found, then the signiﬁcant
variables were compared using a Bonferroni post hoc test.
SPSS version 17 (Chicago, Ill) statistical analysis software
was used to perform all statistical calculations and all data
is presented as means ± SEM.
4. Results
No signiﬁcant diﬀerences between the antioxidant treatment
group (n = 10) and the placebo group (n = 10) were
found in age, height, weight, body mass, VO2peak, or resting
heart rate which are presented in Table 1. There were also
no signiﬁcant diﬀerences between the treatment and placebo
group in PWV (central or peripheral), resting SBP, DBP,
heart rate (HR), or ORAC between groups.
Signiﬁcant diﬀerences were found in 30-minute postex-
ercise systolic blood pressure measurements in the treatment
group following supplementation (Figure 1). The placebo
group had no signiﬁcant SBP changes from before to after
exercise following two weeks of placebo supplementation.
The treatment group, however, had a further signiﬁcant (P<
0.05) decrease in blood pressure following an acute bout of
exercise after antioxidant supplementation.
As shown in Figure 2, AIx also showed a signiﬁcant
reduction in the treatment group following supplemen-
tation. After antioxidant supplementation, AIx showed a
signiﬁcant (P = 0.01) decrease from before to after exercise,
whereas there were no signiﬁcant changes in the placebo
group and no signiﬁcant changes before supplementation.
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Figure 1: The change in systolic blood pressure from before and
after acute exercise for visit 1 (presupplementation/placebo) and
visit 2 (postsupplementation/placebo) amongst the trt group (n =
10) and the placebo group (n = 10). There was a signiﬁcant
decrease in systolic blood pressure following supplementation in
the treatment group after an acute bout of exercise. +denotes
interaction (P = 0.04), ∗denotes signiﬁcance (P<0.05). Values
are means ± SEM.
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Figure 2: Augmentation index before and after acute exercise for
visit 1 (presupplementation/placebo) and visit 2 (postsupplemen-
tation/placebo) for Trt group (n = 10) and placebo group (n =
10). There was a signiﬁcant decrease in augmentation index in the
treatment group following an acute bout of exercise after two weeks
of supplementation. ∗denotes a signiﬁcant change from before to
after exercise (P = 0.01), +denotes a signiﬁcant interaction (P =
0.03) Values are means ± SEM.
A signiﬁcant (P = 0.001) increase was found in FRAP
in the antioxidant supplementation group in the before
exercise measurements. There were no signiﬁcant changes
in the placebo group following placebo supplementation.
Following exercise, there were no signiﬁcant diﬀerences in
FRAP levels in supplement or placebo groups (Figure 3).Oxidative Medicine and Cellular Longevity 5
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Figure 3: FRAP assay results before and after acute exercise for
visit 1 (presupplementation/placebo) and visit 2 (postsupplemen-
tation/placebo) amongst the trt group (n = 10) and the placebo
group (n = 10). There was a signiﬁcant increase in resting FRAP
levels from before to after supplementation in the treatment group
only. ∗denotessigniﬁcancefromvisit1tovisit2(P = 0.001).Values
are means ± SEM.
5. Discussion
Results from the present investigation support the theory
that ingesting a multiﬂavonoid plus ﬁsh oil supplement
in combination with aerobic exercise signiﬁcantly reduces
SBP and AIx at 30 minutes after exercise and signiﬁcantly
increases resting levels of FRAP in postsupplementation
levels compared with presupplementation.
The attenuation of AIx, a measure linked to aortic
arterial stiﬀness, was likely due to the signiﬁcant increase
in FRAP which may have led to greater bioavailability of
NO within the elastic modulus of the aortic vessel. Since
the amount of reﬂected wave was decreased, the amount
of elastic “cushion” had to be augmented to absorb the
pulsatile bolus of blood being ejected from the left ventricle.
The increased expression of NO following ﬂavonoid and
ﬁsh oil supplementation has been shown in many studies
[7, 10]. Interestingly, despite the decrease in AIx, there was
no decrease in PWV as both are considered to be indicators
ormeasuresofarterialstiﬀness.Thisﬁndingisnotsurprising
since it has been shown on several occasions that AIx is not
proportional to PWV in systolic hypertension, but instead
has been shown to be inversely related [20]. In one study by
Vyas et al. [21], AIx was inversely related to aortic PWV and
weakly related to aortic compliance and an increase in AIx
is not a reliable replacement for increased aortic stiﬀness.
However, it did show that higher stiﬀness (increased PWV
and lower compliance) was associated with a lower AIx [21].
The increased distensibility that resulted in a more favorable
augmentation index could be due to the composition of the
matrix of the vessel. The aorta has been shown to have the
largest amount of eNOS potential and the supplement may
have the greatest potential to upregulate this synthase pool.
Although the antioxidant supplementation did not have
any eﬀect on vascular distensibility (PWV) or resting SBP,
the magnitude of PEH was signiﬁcantly decreased in the
30-minute postexercise period after supplementation for the
treatment condition when compared to the placebo without
showing a correlating decrease in HR or PWV. Although
resting SBP did not change with supplementation, there
was a signiﬁcant decrease in the systolic component of
PEH. Because there was no change in PWV, one can only
postulate that arterial distensibility was not the cause of this
reduction in blood pressure. One possible explanation is
that supplementation caused a decrease in oxidative stress,
potentially due to an increase in antioxidant power (an
increase in FRAP). A reduction in ROS would increase the
bioavailability of NO, stimulating vasodilation. A second
theory would be a change in sympathovagal regulation in
which the supplement may induce a sympatholytic eﬀect on
sympathetic tone, thereby increasing the vagal tone.
The results of the present investigation support research
done by Edwards et al. [22] who demonstrated a reduc-
tion in resting blood pressure in hypertensive versus pre-
hypertensive patients following an antioxidant supplemen-
tation regimen of quercetin. Many studies have shown a
beneﬁcialdecreaseinrestingbloodpressureinhypertensives,
indicating the possibility that this decrease in blood pressure
can aﬀect the hypertensive patient but not a normotensive
or pre-hypertensive patient. To those authors’ knowledge,
this is the ﬁrst investigation to support the premise that
prehypertensives may also beneﬁt from an antioxidant and
n-3 fatty acid supplement. This also supports research
demonstrating that antioxidants (like quercetin and Vitamin
C) increased plasma quercetin levels but had no inﬂuence
on oxidative stress or antioxidant capacity measures [23]
and that chronic quercetin ingestion does not protect
against exercise-induced oxidative stress or inﬂammation
[24]. Without this protective mechanism against oxidative
stress, it is possible that NO was not increased. Much of the
research concerning antioxidant use has been shown to have
beneﬁcialeﬀectsinanimalmodels[25–32],butthereisalack
of beneﬁts shown in human models. Speculatively, this could
be due to the dosages ingested by humans being too large to
be absorbed and simply excreted.
The signiﬁcant increase in FRAP in the treatment group
demonstrates that the total plasma antioxidant capacity
increased following supplementation which may be related
to the further decrease in systolic blood pressure during the
postexercise period. This increase in antioxidant capacity
could lead to an increase of free radical scavenging by antiox-
idants, thereby decreasing oxidative stress and potentially
increasing NO levels. An increase of NO in the vasculature
would lead to vasodilation and a further decrease of the
systolic blood pressure after exercise. Interestingly, resting
blood pressure following two weeks of supplementation was
unchanged, demonstrating that a decrease in blood pressure
in the 30-minute postexercise period from antioxidant
supplementation occurred in conjunction with postexercise
vasodilation.
The favorable eﬀects of the supplement could be
due to the multiﬂavonoid plus ﬁsh oil approach, unlike6 Oxidative Medicine and Cellular Longevity
the single antioxidant approach that many previous research
investigations have experimented with. The ingestion of
many of the elements in the supplement has not shown
consistent vascular beneﬁts in humans. Chronic quercetin
ingestion has not been proven to protect against exercise-
induced oxidative stress or inﬂammation [24]. EGCG was
shown to decrease stroke and mortality in stroke-prone,
spontaneously hypertensive rats [11]. In relation to blood
pressure, EGCG has been shown to decrease systolic blood
pressure and enhances endothelial function and insulin
sensitivity of spontaneous hypertensive rats, yet there is a
paucity of the literature regarding the cardiovascular beneﬁts
of EGCG in humans.
People with a high risk of ischemic heart disease and/or
hypertension could beneﬁt from eating ﬁsh as clinical
trials have shown that undergoing supplementation of fatty
acids like ﬁsh oil can improve arterial elasticity in subjects
with diabetes or dyslipidemia and even improved large
arterial elasticity in overweight hypertensive patients [12].
A combination of ﬁsh oil and aerobic exercise has been
shown to be more eﬀective than individual components in
decreasing triglycerides, increasing high-density lipoprotein
(HDL), and improving endothelium dependent arterial
vasodilation [33]. However, results from ﬁsh oil studies
are equivocal. A 12-week double-blind crossover designed
study by Lofgren et al. [34] found no change from pre-
supplementation in systolic or diastolic blood pressure in
middle-aged normotensive men [34].
In conclusion, we have found that a novel multiﬂavonoid
plus ﬁsh oil supplement decreases augmentation index and
systolic blood pressure with concomitant increases in FRAP,
suggesting that cardiovascular beneﬁts may be realized from
this course of supplementation.
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